Revance Therapeutic (RVNC) PT Lowered to $3 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Price: $3.65 --0%
Rating Summary:
4 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
4 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $3.00 (from $7.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $275 at TD Cowen
- Zillow Group (ZG) PT Lowered to $26 at Cantor Fitzgerald
- Modine Manufacturing (MOD) PT Lowered to $178 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
